Milestone
The milestone is full NMPA approval in China for sotatercept, branded locally as Xinruilai, for adults with World Health Organization functional class II or III pulmonary arterial hypertension to improve exercise capacity and functional class. This is a major regulatory event because sotatercept is presented as the first and only approved activin signaling inhibitor in the disease and, more importantly, as the first therapy positioned around causal disease biology rather than purely symptomatic vasodilation.
Disease burden and unmet need
PAH is rare but devastating. Idiopathic pulmonary arterial hypertension historically carried a median survival of roughly 2.8 years and is now included in China's official rare-disease catalog. Symptoms such as dyspnea, fatigue and reduced exercise tolerance often reflect a disease process already driven by progressive small-vessel remodeling and rising pulmonary vascular resistance. Standard therapy improved outcomes, but it did not address the proliferative remodeling that ultimately destroys right ventricular reserve. That is why the field has wanted more than better vasodilation.
Mechanistic rationale
Sotatercept is a recombinant ActRIIA-Fc fusion protein that acts as a ligand trap, reducing excess activin signaling and rebalancing pro-proliferative Smad2/3 activity against anti-proliferative BMPRII-Smad1/5/8 signaling. That mechanism matters because it addresses a recognized signaling imbalance implicated in pulmonary vascular remodeling. Mechanistically, sotatercept is therefore not a best-in-class refinement of existing PAH therapy but a first-in-class attempt to modify disease architecture. That is why its arrival is so important for treatment positioning: the drug is additive to background therapy yet conceptually different from the background therapy itself.
Clinical evidence
China's approval relied primarily on the phase III STELLAR trial, which enrolled 323 adults with PAH receiving stable background therapy. At week 24, patients treated with sotatercept improved six-minute walk distance by 41 meters from baseline, while multiple key secondary endpoints also improved. Most strikingly, STELLAR showed an 84% reduction in the risk of all-cause death or PAH clinical worsening events relative to background therapy alone. The asset's evidence base extends beyond one trial.
Safety and risk-benefit balance
The clinical package supporting China's approval centered on strong efficacy rather than a newly emergent toxicity concern. That said, the relevant analytical point is that a disease-modifying therapy in PAH must justify use on top of complex multidrug background regimens. Sotatercept appears to do so because the magnitude of benefit extends beyond symptomatic exercise measures into hard clinical outcomes. In PAH, that changes the risk-benefit conversation materially. Clinicians will still need to manage class-specific monitoring issues, but a therapy that reduces clinical worsening this substantially is difficult to treat as an optional add-on if access permits.
Therapeutic positioning and competitive landscape
Sotatercept is unlikely to replace all background vasodilator therapy in the near term. Its more realistic role is as a new biologic backbone added to optimized standard regimens, particularly in patients whose risk remains unacceptable despite dual or triple pathway therapy. That positioning can still be highly disruptive because the field has been organized for years around improving combinations of symptomatic drugs. Competitors are now forced to address a different therapeutic benchmark: not only hemodynamic and exercise gains, but credible remodeling-focused disease modification.
Outlook
The approval signals three things at once. Clinically, it confirms that PAH treatment is moving beyond pure vasodilator logic. Regulationally, it shows that China is willing to move quickly on therapies with strong global phase III evidence and clear mechanistic differentiation. Commercially, it creates space for earlier use, broader global uptake and future label expansion as more outcome data mature. The remaining questions are practical: how quickly the drug becomes accessible, whether benefit remains durable across risk strata, and how physicians integrate it into already complex treatment stacks. Even with those questions open, sotatercept's arrival in China is a genuine milestone.